allo-APZ2-ACLF

Biologic

RRHEACELL GmbH & Co. KG

allo-APZ2-ACLF is one of 14 biologic programs targeting Acute-on-Chronic Liver Failure. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute-on-Chronic Liver FailureActive, not recruiting

Acute-on-Chronic Liver FailurePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Acute-on-Chronic Liver Failure

#DrugCompanyPhaseTrials

Glypressin

MMallinckrodt

Approved

1 2

Mesenchymal Stem Cell

RRohto Pharmaceutical Co., Ltd.

Phase 2

1 3

Vastarel

Vemlidy

2 5

Proamatine

Takeda

Preclinical

1 6

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 7

Coreg

Akero Therapeutics

Preclinical

1 8

Tenofovir (TFV) IVR

Gilead

Preclinical

1 9

Plasma Exchange

Sanofi

Preclinical

1 10

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute-on-Chronic Liver Failure1 trial

Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure

Terminated·RRHEACELL GmbH & Co. KG·Phase 1/2·NCT03860155·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for allo-APZ2-ACLF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — allo-APZ2-ACLF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for allo-APZ2-ACLF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RHEACELL GmbH & Co. KG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: RRHEACELL GmbH & Co. KG

allo-APZ2-ACLF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute-on-Chronic Liver Failure1 trial

References

Drug Info

Quick Facts

Related News